Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
暂无分享,去创建一个
Gibril J. Njie | T. Sterling | R. Reves | R. Belknap | D. Menzies | C. R. Horsburgh | P. Lobue | C. Horsburgh | D. Cohn | M. Burgos | C. Winston | C. M. Crane | D. Zenner | Amina Ahmed | C. Horsburgh
[1] T. Sterling,et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. , 2019, The New England journal of medicine.
[2] R. Chaisson,et al. One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis , 2019, The New England journal of medicine.
[3] R. Long,et al. Safety and Side Effects of Rifampin versus Isoniazid in Children , 2018, The New England journal of medicine.
[4] R. Long,et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults , 2018, The New England journal of medicine.
[5] Gibril J. Njie,et al. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection , 2018, MMWR. Morbidity and mortality weekly report.
[6] J. Miro,et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. , 2017, Annals of internal medicine.
[7] Ross J. Harris,et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. , 2017, Annals of internal medicine.
[8] Peter J Dodd,et al. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.
[9] R. Chaisson,et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons , 2016, AIDS.
[10] A. Hill,et al. Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012 , 2015, PloS one.
[11] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[12] S. Yun,et al. Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-γ-releasing assay: an exploratory randomized controlled trial. , 2015, The Journal of antimicrobial chemotherapy.
[13] T. Sterling,et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] M. Conde,et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. , 2015, JAMA pediatrics.
[15] N. Shang,et al. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis , 2015, AIDS.
[16] Guochun Wang,et al. [Preventive therapy for iatrogenic active tuberculosis in systemic lupus erythematosus patients]. , 2014, Zhonghua yi xue za zhi.
[17] Ross J. Harris,et al. Treatment of latent tuberculosis infection: a network meta-analysis. , 2014, Annals of internal medicine.
[18] G. Maartens,et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.
[19] H. Zar,et al. Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[20] J. Kammerer,et al. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. , 2013, American journal of epidemiology.
[21] K. Dooley,et al. Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine , 2013, Antimicrobial Agents and Chemotherapy.
[22] Elie A Akl,et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.
[23] J. Ma,et al. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. , 2013 .
[24] Timothy H. Self,et al. Update on rifampin, rifabutin, and rifapentine drug interactions , 2013, Current medical research and opinion.
[25] M. Jiménez-Fuentes,et al. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[26] Madras.. A Double-blind Placebo-controlled Clinical Trial of Three Antituberculosis Chemoprophylaxis Regimens in Patients with Silicosis in Hong Kong , 2012 .
[27] S. Swaminathan,et al. Efficacy of a Six-Month versus a 36-Month Regimen for Prevention of Tuberculosis in HIV-Infected Persons in India: A Randomized Clinical Trial , 2012, PloS one.
[28] J. Spetz,et al. Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail Inmates , 2012, Journal of correctional health care : the official journal of the National Commission on Correctional Health Care.
[29] P. Shao,et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[30] J. Hackman,et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. , 2011, The New England journal of medicine.
[31] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[32] Nicky J Welton,et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2011 .
[33] R. Chaisson,et al. New regimens to prevent tuberculosis in adults with HIV infection. , 2011, The New England journal of medicine.
[34] Shabir A Madhi,et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. , 2011, The New England journal of medicine.
[35] K. Castro,et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.
[36] C. Bias. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .
[37] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[38] T. Sterling,et al. Latent TB infection treatment acceptance and completion in the United States and Canada. , 2010, Chest.
[39] S. Akhtar,et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] M Elizabeth Halloran,et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics , 2009, Proceedings of the National Academy of Sciences.
[41] F. Wen,et al. [Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy]. , 2009, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.
[42] K. Khan,et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection , 2008, Annals of Internal Medicine.
[43] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[44] L. Myer,et al. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[45] V. Sypsa,et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] M. García,et al. Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infección latente de tuberculosis. Ensayo clínico aleatorizado , 2007 .
[47] Miguel A García,et al. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH , 2007 .
[48] C. Herranz,et al. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. , 2007, Enfermedades infecciosas y microbiologia clinica.
[49] H. Zar,et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial , 2006, BMJ : British Medical Journal.
[50] Richard D Moore,et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. , 2006, American journal of respiratory and critical care medicine.
[51] S. Agarwal,et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy , 2005, Transplant infectious disease : an official journal of the Transplantation Society.
[52] C. F. von Reyn,et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] J. Ena,et al. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] J. Caylà,et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[55] K. Schwartzman,et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. , 2004, American journal of respiratory and critical care medicine.
[56] R. Chaisson,et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] M. G. Torre,et al. Infección tuberculosa latente en población indigente. Comparación de dos pautas terapéuticas , 2004 .
[58] M. García de la Torre,et al. [Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches]. , 2004, Medicina clinica.
[59] S. Agarwal,et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient , 2004, International Urology and Nephrology.
[60] C. Leung,et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. , 2003, Chest.
[61] E. Meriño,et al. Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniacida , 2003 .
[62] Miguel A García,et al. Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea , 2003 .
[63] J. Sánchez-Payá,et al. [Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]. , 2003, Enfermedades infecciosas y microbiologia clinica.
[64] L. Tanoue. Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection—United States, 2003 , 2006 .
[65] A. Rivero,et al. [Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. , 2003, Enfermedades infecciosas y microbiologia clinica.
[66] John L. Johnson,et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults , 2001, AIDS.
[67] J. Pape,et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. , 2001, Journal of acquired immune deficiency syndromes.
[68] D. Fuchs,et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults , 2001, AIDS.
[69] J. Blanch,et al. [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group]. , 2000, Medicina clínica (Ed. impresa).
[70] P. Geijo,et al. Evaluación de dos pautas de quimioprofilaxis tuberculosa en pacientes infectados por el virus de la inmunodeficiencia humana , 2000 .
[71] ohn,et al. A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for Tuberculosis , 2000 .
[72] P. Olliaro,et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[73] G. Comstock. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[74] E. M. Alfaro,et al. Cumplimentación, tolerancia y eficacia de una pauta corta de quimioprofilaxis para el tratamiento de la tuberculosis , 1998 .
[75] R. Chaisson,et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection , 1998, The Lancet.
[76] S. Brooks. MCMC convergence diagnosis via multivariate bounds on log-concave densities , 1998 .
[77] M. Castillejos,et al. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. , 1998, Medicina clinica.
[78] M. Vjecha,et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, New England Journal of Medicine.
[79] W. El-Sadr,et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. , 1997, The New England journal of medicine.
[80] F. Plummer,et al. Isoniazid preventive therapy for tuberculosis in HIV‐1‐infected adults: results of a randomized controlled trial , 1997, AIDS.
[81] R. Cowie. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[82] L. M. Andrade,et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. , 1996, American journal of respiratory and critical care medicine.
[83] U. Wahn,et al. [Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project]. , 1994, Pneumologie.
[84] L. Jeyaseelan,et al. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. , 1994, Transplantation.
[85] J. Pape,et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.
[86] M. A. Steele,et al. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. , 1991, Chest.
[87] Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. , 1982, Bulletin of the World Health Organization.
[88] D. Snider,et al. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. , 2015, The American review of respiratory disease.
[89] A. Falk,et al. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. , 1978, Chest.
[90] I Sutherland,et al. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. , 1976, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.
[91] W. Bailey,et al. The effect of isoniazid on transaminase levels. , 1974, Annals of internal medicine.
[92] F. Lert,et al. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. , 1973, International journal of epidemiology.
[93] W. Stead. Epidemiologic basis of tuberculosis eradication. , 1970, Annals of internal medicine.
[94] Ferebee Sh. Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970 .
[95] S. Ferebee. Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970, Bibliotheca tuberculosea.
[96] Veening Gj. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968 .
[97] G. Veening. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968, Bulletin of the International Union against Tuberculosis.
[98] S. Ferebee,et al. A controlled trial of community-wide isoniazid prophylaxis in Alaska. , 2015, The American review of respiratory disease.
[99] O. Horwitz,et al. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. , 1966, Bulletin of the World Health Organization.
[100] M. Sugimoto,et al. Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report. , 1965, The American review of respiratory disease.
[101] T. Egsmose,et al. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. , 1965, Bulletin of the World Health Organization.
[102] S. Ferebee,et al. A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. , 1963, The American review of respiratory disease.
[103] S. Ferebee,et al. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. , 2015, The American review of respiratory disease.
[104] S. Ferebee,et al. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. , 1962, The American review of respiratory disease.